• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An evaluation of promoter methylation within the methylation subclasses of glioblastoma.

作者信息

Alnahhas Iyad, LaHaye Stephanie, Giglio Pierre, Mardis Elaine, Puduvalli Vinay

机构信息

Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.

出版信息

Neurooncol Adv. 2020 Nov 16;2(1):vdaa117. doi: 10.1093/noajnl/vdaa117. eCollection 2020 Jan-Dec.

DOI:10.1093/noajnl/vdaa117
PMID:33880446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8044669/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7a/8044669/dfb4a40027ac/vdaa117_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7a/8044669/dfb4a40027ac/vdaa117_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7a/8044669/dfb4a40027ac/vdaa117_fig1.jpg

相似文献

1
An evaluation of promoter methylation within the methylation subclasses of glioblastoma.胶质母细胞瘤甲基化亚类中启动子甲基化的评估
Neurooncol Adv. 2020 Nov 16;2(1):vdaa117. doi: 10.1093/noajnl/vdaa117. eCollection 2020 Jan-Dec.
2
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.不可切除胶质母细胞瘤的预后：MGMT 启动子甲基化起关键作用。
J Neurol. 2017 Feb;264(2):350-358. doi: 10.1007/s00415-016-8355-1. Epub 2016 Dec 5.
3
High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.原发性胶质母细胞瘤中MGMT启动子甲基化发生率高，与TP53基因突变无关。
Cancer Genet Cytogenet. 2009 Jan 15;188(2):77-82. doi: 10.1016/j.cancergencyto.2008.09.015.
4
The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.TERT 启动子突变状态和 MGMT 启动子甲基化状态，结合 MRI 衍生的和临床特征的二分法，可预测成人原发性胶质母细胞瘤的生存。
Cancer Med. 2018 Aug;7(8):3704-3712. doi: 10.1002/cam4.1666. Epub 2018 Jul 9.
5
Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.基于感兴趣区分析的结构和高级影像学预测原发性胶质母细胞瘤 MGMT 启动子甲基化。
BMC Cancer. 2018 Feb 21;18(1):215. doi: 10.1186/s12885-018-4114-2.
6
Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.通过MGMT启动子甲基化分层的胶质母细胞瘤亚组中，成像参数对预测假性进展的不同诊断价值。
Eur Radiol. 2017 Jan;27(1):255-266. doi: 10.1007/s00330-016-4346-y. Epub 2016 Apr 5.
7
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.弱 MGMT 基因启动子甲基化可为新诊断的胶质母细胞瘤患者带来显著的临床生存获益：一项回顾性队列研究。
J Neurooncol. 2020 Jan;146(1):55-62. doi: 10.1007/s11060-019-03334-5. Epub 2019 Nov 7.
8
Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.糖原合酶激酶 3β 抑制通过 c-Myc 信号通路影响 O6-甲基鸟嘌呤 DNA 甲基转移酶启动子甲基化，从而增强人脑胶质瘤细胞对替莫唑胺的敏感性。
Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28.
9
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.MGMT C>T（rs16906252）增强子单核苷酸多态性（SNP）的 T 基因型与胶质母细胞瘤患者的启动子甲基化和更长的生存时间相关。
Eur J Cancer. 2013 Jan;49(2):360-8. doi: 10.1016/j.ejca.2012.08.012. Epub 2012 Sep 10.
10
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.确定MGMT基因启动子甲基化的临界值及其在胶质母细胞瘤中的预测能力。
J Neurooncol. 2016 Jun;128(2):333-9. doi: 10.1007/s11060-016-2116-y. Epub 2016 Mar 30.

引用本文的文献

1
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.KL-50，一种用于治疗耐药性脑癌的咪唑并四嗪候选药物的作用机制。
J Am Chem Soc. 2024 Jul 10;146(27):18241-18252. doi: 10.1021/jacs.3c06483. Epub 2024 May 30.
2
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.在接受替莫唑胺治疗的原发性胶质母细胞瘤患者中，MMR、MGMT 启动子甲基化和蛋白表达对总生存期和无进展生存期的影响。
Int J Mol Sci. 2023 Mar 24;24(7):6184. doi: 10.3390/ijms24076184.

本文引用的文献

1
DNA methylation-based classification of central nervous system tumours.基于 DNA 甲基化的中枢神经系统肿瘤分类。
Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.
2
Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant.弥漫性中线胶质瘤，H3 K27M突变型中MGMT启动子甲基化缺失。
Acta Neuropathol Commun. 2017 Dec 15;5(1):98. doi: 10.1186/s40478-017-0500-2.
3
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
胶质瘤内在基因表达亚型的肿瘤进化与微环境中的免疫变化相关。
Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003.
4
Advances in the molecular genetics of gliomas - implications for classification and therapy.胶质母细胞瘤的分子遗传学进展——对分类和治疗的影响。
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29.
5
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.分子分析揭示弥漫性胶质瘤的生物学离散亚群和进展途径。
Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.
6
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.H3F3A 和 IDH1 热点突变定义了胶质母细胞瘤的独特表观遗传和生物学亚群。
Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024.
7
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.鉴定出一种 CpG 岛甲基化表型，它定义了神经胶质瘤的一个独特亚群。
Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15.
8
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.整合基因组分析确定了具有 PDGFRA、IDH1、EGFR 和 NF1 异常的胶质母细胞瘤的临床相关亚型。
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.
9
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.全面的基因组特征分析确定了人类胶质母细胞瘤的基因和核心通路。
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4.
10
MGMT gene silencing and benefit from temozolomide in glioblastoma.MGMT基因沉默与胶质母细胞瘤对替莫唑胺的获益
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.